Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins.

Kling A, Lukat P, Almeida DV, Bauer A, Fontaine E, Sordello S, Zaburannyi N, Herrmann J, Wenzel SC, König C, Ammerman NC, Barrio MB, Borchers K, Bordon-Pallier F, Brönstrup M, Courtemanche G, Gerlitz M, Geslin M, Hammann P, Heinz DW, Hoffmann H, Klieber S, Kohlmann M, Kurz M, Lair C, Matter H, Nuermberger E, Tyagi S, Fraisse L, Grosset JH, Lagrange S, Müller R.

Science. 2015 Jun 5;348(6239):1106-12. doi: 10.1126/science.aaa4690.

PMID:
26045430
2.

Inhibitors of Civ1 kinase belonging to 6-aminoaromatic-2-cyclohexyldiamino purine series as potent anti-fungal compounds.

Bordon-Pallier F, Jullian N, Ferrari P, Girard AM, Bocquel MT, Biton J, Bouquin N, Haesslein JL.

Biochim Biophys Acta. 2004 Mar 11;1697(1-2):211-23. Review.

PMID:
15023362
3.

The cell cycle of pathogenic fungi: target for drugs.

Bordon-Pallier F, Jullian N, Haesslein JL.

Prog Cell Cycle Res. 2003;5:81-90. Review.

PMID:
14593703
4.

Complete glycosylphosphatidylinositol anchors are required in Candida albicans for full morphogenesis, virulence and resistance to macrophages.

Richard M, Ibata-Ombetta S, Dromer F, Bordon-Pallier F, Jouault T, Gaillardin C.

Mol Microbiol. 2002 May;44(3):841-53.

5.

Tagging morphogenetic genes by insertional mutagenesis in the yeast Yarrowia lipolytica.

Richard M, Quijano RR, Bezzate S, Bordon-Pallier F, Gaillardin C.

J Bacteriol. 2001 May;183(10):3098-107.

Supplemental Content

Loading ...
Support Center